Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with Glioblastoma

Journal of Clinical Oncology

Volumn 33, Issue 10, 2015, Pages 1197-1213

  Lu Emerson, Christine ^a   Duda, Dan G ^a   Emblem, Kyrre E ^a   Taylor, Jennie W ^a   Gerstner, Elizabeth R ^a   Loeffler, Jay S ^b   Batchelor, Tracy T ^b   Jain, Rakesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; TUMOR MARKER; VASCULOTROPIN INHIBITOR; BEVACIZUMAB; CEDIRANIB; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VOLUME; CANCER PATIENT; CANCER RESISTANCE; CANCER TISSUE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; PRIORITY JOURNAL; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); METABOLISM; SURVIVAL ANALYSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84925632920     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.9575     Document Type: Article

References (218)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
2. Ballman KV, Buckner JC, Brown PD, et al: The relationship between six-month progressionfree survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9:29-38, 2007
3. Lamborn KR, Yung WK, Chang SM, et al: Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170, 2008
4. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
5. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
6. Jain RK: Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol 31:2205-2218, 2013
7. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
8. Ferrara N, Hillan KJ, Gerber HP, et al: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400, 2004
9. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
10. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
11. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007
12. Chinot OL, Wick W, Mason W, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014
13. Gilbert MR, Dignam JJ, Armstrong TS, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699-708, 2014
14. Batchelor TT, Mulholland P, Neyns B, et al: Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212-3218, 2013
15. Wick W, Puduvalli VK, Chamberlain MC, et al: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168-1174, 2010
16. Batchelor TT, Gerstner ER, Emblem KE, et al: Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 110:19059-19064, 2013
17. Sorensen AG, Emblem KE, Polaskova P, et al: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72:402-407, 2012
18. Conrad C, Friedman H, Reardon D, et al: A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 22:15s, 2004 (suppl; abstr 1512)
19. Aquino D, Di Stefano AL, Scotti A, et al: Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan. PLoS One 9:e90535, 2014
20. Carmeliet P, Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307, 2011
21. Rege TA, Fears CY, Gladson CL: Endogenous inhibitors of angiogenesis in malignant gliomas: Nature's antiangiogenic therapy. Neuro Oncol 7:106-121, 2005
22. Guo P, Hu B, Gu W, et al: Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162:1083-1093, 2003
23. Jain RK: Molecular regulation of vessel maturation. Nat Med 9:685-693, 2003
24. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
25. Plate KH, Mennel HD: Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol 47:89-94, 1995
26. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004
27. Jain RK, di Tomaso E, Duda DG, et al: Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622, 2007
28. Jain RK, Tong RT, Munn LL: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model. Cancer Res 67:2729-2735, 2007
29. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
30. Tong RT, Boucher Y, Kozin SV, et al: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736, 2004
31. Yuan F, Chen Y, Dellian M, et al: Timedependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/ vascular permeability factor antibody. Proc Natl Acad Sci U S A 93:14765-14770, 1996
32. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
33. Huang Y, Goel S, Duda DG, et al: Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73:2943-2948, 2013
34. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432:396-401, 2004
35. Calabrese C, Poppleton H, Kocak M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82, 2007
36. Lotti F, Jarrar AM, Pai RK, et al: Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 210:2851-2872, 2013
37. Goel HL, Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer 13:871-882, 2013
38. Kim H, Catana C, Ratai EM, et al: Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res 71:3745-3752, 2011
39. El Hallani S, Boisselier B, Peglion F, et al: A new alternative mechanism in glioblastoma vascularization: Tubular vasculogenic mimicry. Brain 133: 973-982, 2010
40. Ricci-Vitiani L, Pallini R, Biffoni M, et al: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824-828, 2010
41. Zuniga RM, Torcuator R, Jain R, et al: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329-336, 2009
42. Soda Y, Marumoto T, Friedmann-Morvinski D, et al: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A 108:4274-4280, 2011
43. Song S, Ewald AJ, Stallcup W, et al: PDGFRbeta + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7:870-879, 2005
44. Reardon DA, Desjardins A, Peters K, et al: Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 103:371-379, 2011
45. Reardon DA, Desjardins A, Peters KB, et al: Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 107:155-164, 2012
46. Reardon DA, Desjardins A, Vredenburgh JJ, et al: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A phase II study. Br J Cancer 101:1986-1994, 2009
47. Desjardins A, Reardon DA, Coan A, et al: Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302-1312, 2012
48. Brat DJ, Bellail AC, Van Meir EG: The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7:122-133, 2005
49. Taal W, Oosterkamp HM, Walenkamp AM, et al: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943-953, 2014
50. Lorgis V, Maura G, Coppa G, et al: Relation between bevacizumab dose intensity and highgrade glioma survival: A retrospective study in two large cohorts. J Neurooncol 107:351-358, 2012
51. Wang R, Chadalavada K, Wilshire J, et al: Glioblastoma stem-like cells give rise to tumor endothelium. Nature 468:829-833, 2010
52. Raizer JJ, Grimm S, Chamberlain MC, et al: A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116:5297-5305, 2010
53. Hasselbalch B, Lassen U, Hansen S, et al: Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial. Neuro Oncol 12:508-516, 2010
54. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12:1300-1310, 2010
55. Lai A, Tran A, Nghiemphu PL, et al: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142-148, 2011
56. Narayana A, Gruber D, Kunnakkat S, et al: A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116:341-345, 2012
57. Vredenburgh JJ, Desjardins A, Reardon DA, et al: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119-4124, 2011
58. Wick W, Cloughesy TF, Nishikawa R, et al: Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 31:114s, 2013 (suppl 15s; abstr 2002)
59. Holash J, Davis S, Papadopoulos N, et al: VEGFTrap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398, 2002
60. Konner J, Dupont J: Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 4:S81-S85, 2004
61. Gomez-Manzano C, Holash J, Fueyo J, et al: VEGF trap induces antiglioma effect at different stages of disease. Neuro Oncol 10:940-945, 2008
62. de Groot JF, Lamborn KR, Chang SM, et al: Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol 29:2689-2695, 2011
63. Shah GD, Loizos N, Youssoufian H, et al: Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer 116:1018-1026, 2010
64. Youssoufian H, Amato RJ, Sweeney CJ, et al: Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFR {alpha} in patients with advanced solid malignancies. J Clin Oncol 26:636s, 2008 (suppl; abstr 14617)
65. Spratlin J: Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 13:97-102, 2011
66. Kopp HG, Ramos CA, Rafii S: Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 13:175-181, 2006
67. Abounader R, Laterra J: Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7:436-451, 2005
68. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005
69. Batchelor TT, Duda DG, di Tomaso E, et al: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823, 2010
70. Quant EC, Norden AD, Drappatz J, et al: Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11:550-555, 2009
71. Goldbrunner RH, Bendszus M, Wood J, et al: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55:426-432, 2004
72. Reardon DA, Egorin MJ, Desjardins A, et al: Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115:2188-2198, 2009
73. Gerstner ER, Eichler AF, Plotkin SR, et al: Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol 103:325-332, 2010
74. Brandes AA, Stupp R, Hau P, et al: EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 46:348-354, 2010
75. Iwamoto FM, Lamborn KR, Robins HI, et al: Phase II trial of pazopanib (GW786034), an oral multitargeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 12:855-861, 2010
76. Kreisl TN, Smith P, Sul J, et al: Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 111:41-48, 2013
77. Neyns B, Sadones J, Chaskis C, et al: Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103:491-501, 2011
78. Pan E, Yu D, Yue B, et al: A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol 110:111-118, 2012
79. Reardon DA, Vredenburgh JJ, Coan A, et al: Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol 105: 621-627, 2011
80. Lee EQ, Kuhn J, Lamborn KR, et al: Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol 14:1511-1518, 2012
81. Peereboom DM, Ahluwalia MS, Ye X, et al: NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 15:490-496, 2013
82. Reiss Y, Machein MR, Plate KH: The role of angiopoietins during angiogenesis in gliomas. Brain Pathol 15:311-317, 2005
83. Gerald D, Chintharlapalli S, Augustin HG, et al: Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy. Cancer Res 73:1649-1657, 2013
84. Chae SS, Kamoun WS, Farrar CT, et al: Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16:3618-3627, 2010
85. Hashizume H, Falcón BL, Kuroda T, et al: Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70:2213-2223, 2010
86. Sulman EP, Won M, Blumenthal DT, et al: Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 31: 116s, 2013 (suppl 15s; abstr LBA2010)
87. Sathornsumetee S, Cao Y, Marcello JE, et al: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271-278, 2008
88. DePrimo S, Wu B, Huang S, et al: Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme. J Clin Oncol 27:99s, 2009 (suppl; abstr 2049)
89. Quant EC, Batchelor T, Lassman AB, et al: Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma. J Clin Oncol 29: 157s, 2011 (suppl; abstr 2069)
90. Nishikawa R, Saran F, Mason W, et al: Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM). J Clin Oncol 31:119s, 2013 (suppl 15s; abstr 2023)
91. de Groot JF, Piao Y, Tran H, et al: Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 17:4872-4881, 2011
92. Sorensen AG, Batchelor TT, Zhang WT, et al: A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296-5300, 2009
93. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338, 2009
94. Sawlani RN, Raizer J, Horowitz SW, et al: Glioblastoma: A method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-Pilot study. Radiology 255:622-628, 2010
95. Schmidt NO, Westphal M, Hagel C, et al: Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84:10-18, 1999
96. Stefanik DF, Rizkalla LR, Soi A, et al: Acidic and basic fibroblast growth factors are present in glioblastoma multiforme and normal brain. Ann N Y Acad Sci 638:477-480, 1991
97. Yancopoulos GD, Davis S, Gale NW, et al: Vascular-specific growth factors and blood vessel formation. Nature 407:242-248, 2000
98. Gomez-Manzano C, Fueyo J, Jiang H, et al: Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53:109-117, 2003
99. Morrison RS, Gross JL, Herblin WF, et al: Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line. Cancer Res 50:2524-2529, 1990
100. Lockhart AC, Rothenberg ML, Dupont J, et al: Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28:207-214, 2010
101. Deryugina EI, Quigley JP: Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochim Biophys Acta 1803:103-120, 2010
102. Wesolowska A, Kwiatkowska A, Slomnicki L, et al: Microglia-derived TGF-beta as an important regulator of glioblastoma invasion: An inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 27:918-930, 2008
103. Bogdahn U, Hau P, Stockhammer G, et al: Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study. Neuro Oncol 13:132-142, 2011
104. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007
105. Drappatz J, Norden AD, Wong ET, et al: Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 78:85-90, 2010
106. Reardon DA, Conrad CA, Cloughesy T, et al: Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 69:1507-1518, 2012
107. Matsui J, Yamamoto Y, Funahashi Y, et al: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664-671, 2008
108. Graff JR, McNulty AM, Hanna KR, et al: The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462-7469, 2005
109. Jiang BH, Zheng JZ, Aoki M, et al: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 97:1749-1753, 2000
110. Yoshiji H, Kuriyama S, Ways DK, et al: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59: 4413-4418, 1999
111. Drappatz J, Wong ET, Schiff D, et al: A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73:222-227, 2009
112. Fadul C, Kingman L, Meyer L, et al: A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol 90:229-235, 2008
113. Fine HA, Figg WD, Jaeckle K, et al: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715, 2000
114. Fine HA, Wen PY, Maher EA, et al: Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21:2299-2304, 2003
115. Zustovich F, Cartei G, Ceravolo R, et al: A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors. Anticancer Res 27:1019-1024, 2007
116. Chang SM, Lamborn KR, Malec M, et al: Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60: 353-357, 2004
117. Gilbert MR, Gonzalez J, Hunter K, et al: A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol 12:1167-1172, 2010
118. Kesari S, Schiff D, Henson JW, et al: Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 10:300-308, 2008
119. Tuettenberg J, Grobholz R, Korn T, et al: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31-40, 2005
120. Nabors LB, Fiveash JB, Markert JM, et al: A phase 1 trial of ABT-510 concurrent with standard chemoradiotherapy for patients with newly diagnosed glioblastoma. Arch Neurol 67:313-319, 2010
121. Khasraw M, Holodny A, Goldlust SA, et al: Intracranial hemorrhage in patients with cancer treated with bevacizumab: The Memorial Sloan-Kettering experience. Ann Oncol 23:458-463, 2012
122. Bähr O, Hattingen E, Rieger J, et al: Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol 13:1020-1029, 2011
123. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
124. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
125. Sorensen AG, Batchelor TT, Wen PY, et al: Response criteria for glioma. Nat Clin Pract Oncol 5:634-644, 2008
126. van den Bent MJ, Vogelbaum MA, Wen PY, et al: End point assessment in gliomas: Novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 27:2905-2908, 2009
127. Sorensen AG, Patel S, Harmath C, et al: Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 19:551-557, 2001
128. Pichler J, Pachinger C, Pelz M, et al: MRI assessment of relapsed glioblastoma during treatment with bevacizumab: Volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression-A pilot study. Eur J Radiol 82:e240-e245, 2013
129. Liberman G, Louzoun Y, Aizenstein O, et al: Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma. Eur J Radiol 82:e87-e94, 2013
130. de Wit MC, de Bruin HG, Eijkenboom W, et al: Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535-537, 2004
131. Brandsma D, Stalpers L, Taal W, et al: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461, 2008
132. Wong TZ, van der Westhuizen GJ, Coleman RE: Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12:615-626, 2002
133. Chen W: Clinical applications of PET in brain tumors. J Nucl Med 48:1468-1481, 2007
134. Schwarzenberg J, Czernin J, Cloughesy TF, et al: 3″-deoxy-3″-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 53:29-36, 2012
135. Harris RJ, Cloughesy TF, Pope WB, et al: 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 14:1079-1089, 2012
136. Hasselbalch B, Eriksen JG, Broholm H, et al: Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 118:585-594, 2010
137. Lu-Emerson C, Snuderl M, Kirkpatrick ND, et al: Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol 15:1079-1087, 2013
138. Chen C, Huang R, MacLean A, et al: Recurrent high-grade glioma treated with bevacizumab: Prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 115:267-276, 2013
139. Lv S, Teugels E, Sadones J, et al: Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res 31:4457-4463, 2011
140. Galanis E, Anderson SK, Lafky JM, et al: Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): A North Central Cancer Treatment Group trial. Clin Cancer Res 19:4816-4823, 2013
141. Duda DG, Willett CG, Ancukiewicz M, et al: Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 15:577-583, 2010
142. Tabouret E, Boudouresque F, Barrie M, et al: Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol 16:392-399, 2014
143. Waldman AD, Jackson A, Price SJ, et al: Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol 6:445-454, 2009
144. Gerstner ER, Batchelor TT: Imaging and response criteria in gliomas. Curr Opin Oncol 22:598-603, 2010
145. Jarzabek MA, Sweeney KJ, Evans RL, et al: Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): An integrated multidisciplinary commentary. Drug Discov Today 18:1052-1066, 2013
146. Covarrubias DJ, Rosen BR, Lev MH: Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 9:528-537, 2004
147. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for highgrade gliomas: Response assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963-1972, 2010
148. Ellingson BM, Cloughesy TF, Lai A, et al: Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:401-409, 2011
149. Gorlia T, Stupp R, Brandes AA, et al: New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 48:1176-1184, 2012
150. O'Connor JP, Jackson A, Parker GJ, et al: Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 9:167-177, 2012
151. Emblem KE, Mouridsen K, Bjornerud A, et al: Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 19:1178-1183, 2013
152. Gerstner ER, Sorensen AG: Diffusion and diffusion tensor imaging in brain cancer. Semin Radiat Oncol 21:141-146, 2011
153. Moffat BA, Chenevert TL, Lawrence TS, et al: Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102:5524-5529, 2005
154. Hamstra DA, Galbán CJ, Meyer CR, et al: Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387-3394, 2008
155. Pope WB, Qiao XJ, Kim HJ, et al: Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: A multicenter study. J Neurooncol 108:491-498, 2012
156. Kothari PD, White NS, Farid N, et al: Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab. AJNR Am J Neuroradiol 34:1752-1757, 2013
157. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603, 2008
158. di Tomaso E, Snuderl M, Kamoun WS, et al: Glioblastoma recurrence after cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape. Cancer Res 71:19-28, 2011
159. Gerstner ER, Chen PJ, Wen PY, et al: Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12:466-472, 2010
160. Gerstner ER, Frosch MP, Batchelor TT: Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 28:e91-e93, 2010
161. de Groot JF, Fuller G, Kumar AJ, et al: Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice. Neuro Oncol 12:233-242, 2010
162. Gerstner ER, Levine M, Ye X, et al: A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. J Clin Oncol 31:127s, 2013 (suppl 15s; abstr 2054)
163. Henriksson R, Asklund T, Poulsen HS: Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: A review. J Neurooncol 104:639-646, 2011
164. Francesconi AB, Dupre S, Matos M, et al: Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 17:970-974, 2010
165. Chamberlain MC, Johnston SK: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96:259-269, 2010
166. Nghiemphu PL, Liu W, Lee Y, et al: Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience. Neurology 72: 1217-1222, 2009
167. Ali SA, McHayleh WM, Ahmad A, et al: Bevacizumab and irinotecan therapy in glioblastoma multiforme: A series of 13 cases. J Neurosurg 109:268-272, 2008
168. Kang TY, Jin T, Elinzano H, et al: Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol 89:113-118, 2008
169. Bokstein F, Shpigel S, Blumenthal DT: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112:2267-2273, 2008
170. Pope WB, Lai A, Nghiemphu P, et al: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260, 2006
171. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol 7:369, 2005 (abstr 342)
172. Scott BJ, Quant EC, McNamara MB, et al: Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 12:603-607, 2010
173. Goldlust SA, Cavaliere R, Newton HB, et al: Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J Neurooncol 107:407-411, 2012
174. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787, 2008
175. Reardon D, Friedman H, Yung WK, et al: A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 22:28s, 2004 (suppl; abstr 1513)
176. Kreisl TN, McNeill KA, Sul J, et al: A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol 14:1519-1526, 2012
177. Reardon DA, Vredenburgh JJ, Desjardins A, et al: Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101:57-66, 2011
178. Hainsworth JD, Ervin T, Friedman E, et al: Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the firstline treatment of patients with glioblastoma multiforme. Cancer 116:3663-3669, 2010
179. Drappatz J, Brenner AJ, Rosenfeld S, et al: ANG1005: Results of a phase I study in patients with recurrent malignant glioma. J Clin Oncol 28:182s, 2010 (suppl; abstr 2009)
180. Jain RK: Antiangiogenesis strategies revisted: From starving tumors to alleviating hypoxia. Cancer Cell 26:605-622, 2014
181. Rieger J, Bähr O, Müller K, et al: Bevacizumabinduced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99:49-56, 2010
182. Ferl GZ, Xu L, Friesenhahn M, et al: An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: Application to glioblastoma treated with bevacizumab. Magn Reson Med 63:1366-1375, 2010
183. Jain R, Scarpace LM, Ellika S, et al: Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 96:423-431, 2010
184. Nowosielski M, Recheis W, Goebel G, et al: ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 53:291-302, 2011
185. Hwang EI, Jakacki RI, Fisher MJ, et al: Longterm efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 60:776-782, 2013
186. Ratai EM, Zhang Z, Snyder BS, et al: Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN6677. Neuro Oncol 15:936-944, 2013
187. Hsu YH, Ferl GZ, Ng CM: GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. Magn Reson Imaging 31:618-623, 2013
188. Desjardins A, Barboriak DP, Herndon JE II, et al: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). J Clin Oncol 25:82s, 2007 (suppl; abstr 2029)
189. Pope WB, Kim HJ, Huo J, et al: Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182-189, 2009
190. Ellingson BM, Malkin MG, Rand SD, et al: Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and antiangiogenic treatments in malignant gliomas. J Neurooncol 102:95-103, 2011
191. Ellingson BM, Cloughesy TF, Lai A, et al: Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med 67:237-245, 2012
192. Hwang EJ, Cha Y, Lee AL, et al. Early response evaluation for recurrent high grade gliomas treated with bevacizumab: A volumetric analysis using diffusion-weighted imaging. J Neurooncol 112:427-435, 2013
193. Chen W, Delaloye S, Silverman DH, et al: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25:4714-4721, 2007
194. Schiepers C, Dahlbom M, Chen W, et al: Kinetics of 3″-deoxy-3″-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med 51:720-727, 2010
195. Wardak M, Schiepers C, Dahlbom M, et al: Discriminant analysis of 18F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res 17:6553-6562, 2011
196. Hutterer M, Nowosielski M, Putzer D, et al: O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52:856-864, 2011
197. Colavolpe C, Chinot O, Metellus P, et al: FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol 14:649-657, 2012
198. Galldiks N, Rapp M, Stoffels G, et al: Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-Ltyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40:22-33, 2013
199. Vidiri A, Pace A, Fabi A, et al: Early perfusion changes in patients with recurrent high-grade brain tumor treated with bevacizumab: Preliminary results by a quantitative evaluation. J Exp Clin Cancer Res 31:33, 2012
200. Ellingson BM, Cloughesy TF, Lai A, et al: Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol 106:111-119, 2012
201. Gupta A, Young RJ, Karimi S, et al: Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol 32:1301-1306, 2011
202. Mong S, Ellingson BM, Nghiemphu PL, et al: Persistent diffusion-restricted lesions in bevacizumabtreated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 33:1763-1770, 2012
203. LaViolette PS, Cohen AD, Prah MA, et al: Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. Neuro Oncol 15:442-450, 2013
204. Grommes C, Karimi S, Beal K, et al: FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM). J Clin Oncol 29:152s, 2011 (suppl; abstr 2048)
205. Pope WB, Lai A, Mehta R, et al: Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 32:882-889, 2011
206. Emblem KE, Bjornerud A, Mouridsen K, et al: T(1)- and T(2)()-dominant extravasation correction in DSC-MRI: Part II. Predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. Cereb Blood Flow Metab 31:2054-2064, 2011
207. Emblem KE, Batchelor TT, Gerstner ER, et al: Glioblastoma patients with arterio-venous normalization during anti-angiogenic therapy have prolonged survival. Eur J Cancer 49:S29, 2013 (abstr MC13-0062)
208. Reardon DA, Fink KL, Mikkelsen T, et al: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610-5617, 2008
209. O'Neill Blakeley J, Fisher JD, Lieberman FS, et al: Imaging biomarkers of ramucirumab and olaratumab in patients with recurrent glioblastoma. J Clin Oncol 31:125s, 2013 (suppl 15s; abstr 2044)
210. Sorensen AG, Jenning D, Wang M, et al: Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study. J Clin Oncol 27:99s, 2009 (suppl 15S; abstr 2048)
211. Lupo JM, Essock-Burns E, Molinaro AM, et al: Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol 15:480-489, 2013
212. Essock-Burns E, Lupo JM, Cha S, et al: Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 13:119-131, 2011
213. Cha S, Knopp EA, Johnson G, et al: Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 21:881-890, 2000
214. Akella NS, Twieg DB, Mikkelsen T, et al: Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial. J Magn Reson Imaging 20:913-922, 2004
215. Nabors LB, Mikkelsen T, Rosenfeld SS, et al: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657, 2007
216. Neyns B, Sadones J, Chaskis C, et al: A phase II trial of sunitinib malate in patients with recurrent highgrade glioma. J Neurooncol 103:491-501, 2011
217. Neyns B, Chaskis C, Dujardin M, et al: Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. J Clin Oncol 27:96s, 2009 (suppl 15S; abstr 2038)
218. Wen PY Prados M, Schiff D, et al: Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J Clin Oncol 28:181s, 2010 (suppl; abstr 2006)